SLC5A2 and hydrops fetalis: A posthoc analysis of 79 patients with acute HF participating in the EMPA-RESPONSE-AHF study, which comparatively assessed treatment with a sodium-dependent glucose-cotransporter protein 2 (SGLT-2) inhibitor, empagliflozin, for one month, with placebo therapy in patients with acute HF, showed that ketone body levels in the circulation, and particularly acetone, were significantly raised during an event of acute decompensated HF versus the period following stabilization [45].